| Patient Characteristics . | No. (%) or Median (IQR) . |
|---|---|
| Age, years | 43.5 (36.5–48.5) |
| Male sex | 10 (71) |
| Previous TB treatment, yes | 5 (36) |
| Positive HIV status | 1 (7) |
| Diabetes, yes | 5 (36) |
| Site of disease | |
| Pulmonary | 14 (100) |
| Both pulmonary and extrapulmonary | 5 (36) |
| Sputum smear positivea | 9 (69) |
| Sputum culture positive | 14 (100) |
| CXR, abnormal | 12 (86) |
| Cavitary | 7 (58) |
| Drug-resistance profile | |
| MDR | 3 (21) |
| Resistance to INH, RIF, EMB, PZA (AFLDR) | 4 (29) |
| Pre-XDR (FQN-resistant) | 4 (29) |
| XDR | 3 (21) |
| Number of effective drugs in regimen | |
| Intensive phaseb | 7 (5–9) |
| Continuation phasec | 5 (4–6) |
| Duration of MDR therapy, days | 768 (687–858.5) |
| Time on therapy before BDQ start, days | 94 (37–443) |
| Indication for BDQ | |
| Extensive resistance | 8 (57) |
| Rx failure | 1 (7) |
| Intolerance to drugs | 6 (43) |
| Poor clinical response to treatment | 2 (14) |
| Duration of BDQ use, days | 173 (165–193) |
| Payment for BDQ | |
| Private insurance | 5 (36) |
| Government plan | 2 (14) |
| State/local HD | 5 (36) |
| Other | 2 (14) |
| Time to culture conversion, days | 71 (26–116) |
| Treatment outcomes | |
| Completed | 12 (86) |
| Moved out of country | 1 (7) |
| Died on treatment | 1 (7) |
| Patient Characteristics . | No. (%) or Median (IQR) . |
|---|---|
| Age, years | 43.5 (36.5–48.5) |
| Male sex | 10 (71) |
| Previous TB treatment, yes | 5 (36) |
| Positive HIV status | 1 (7) |
| Diabetes, yes | 5 (36) |
| Site of disease | |
| Pulmonary | 14 (100) |
| Both pulmonary and extrapulmonary | 5 (36) |
| Sputum smear positivea | 9 (69) |
| Sputum culture positive | 14 (100) |
| CXR, abnormal | 12 (86) |
| Cavitary | 7 (58) |
| Drug-resistance profile | |
| MDR | 3 (21) |
| Resistance to INH, RIF, EMB, PZA (AFLDR) | 4 (29) |
| Pre-XDR (FQN-resistant) | 4 (29) |
| XDR | 3 (21) |
| Number of effective drugs in regimen | |
| Intensive phaseb | 7 (5–9) |
| Continuation phasec | 5 (4–6) |
| Duration of MDR therapy, days | 768 (687–858.5) |
| Time on therapy before BDQ start, days | 94 (37–443) |
| Indication for BDQ | |
| Extensive resistance | 8 (57) |
| Rx failure | 1 (7) |
| Intolerance to drugs | 6 (43) |
| Poor clinical response to treatment | 2 (14) |
| Duration of BDQ use, days | 173 (165–193) |
| Payment for BDQ | |
| Private insurance | 5 (36) |
| Government plan | 2 (14) |
| State/local HD | 5 (36) |
| Other | 2 (14) |
| Time to culture conversion, days | 71 (26–116) |
| Treatment outcomes | |
| Completed | 12 (86) |
| Moved out of country | 1 (7) |
| Died on treatment | 1 (7) |
N = 14.
Abbreviations: AFLDR, all first-line drug resistant; BDQ, bedaquiline; CXR, chest X-ray; EMB, ethambutol; FQN, fluoroquinolone; HD, health department; HIV, human immunodeficiency virus; INH, isoniazid; IQR, interquartile range; MDR, multidrug-resistant; PZA, pyrazinamide; RIF, rifampin; XDR, extensively drug-resistant; TB, tuberculosis.
aOne smear not done. Denominator out of 13.
bIntensive-phase effective drugs: number of drugs in treatment regimen the patient was sensitive to or otherwise determined effective, while taking any injectable.
cContinuation-phase effective drugs: number of drugs in treatment regimen the patient was sensitive to or otherwise determined effective, after injectables had been discontinued.
| Patient Characteristics . | No. (%) or Median (IQR) . |
|---|---|
| Age, years | 43.5 (36.5–48.5) |
| Male sex | 10 (71) |
| Previous TB treatment, yes | 5 (36) |
| Positive HIV status | 1 (7) |
| Diabetes, yes | 5 (36) |
| Site of disease | |
| Pulmonary | 14 (100) |
| Both pulmonary and extrapulmonary | 5 (36) |
| Sputum smear positivea | 9 (69) |
| Sputum culture positive | 14 (100) |
| CXR, abnormal | 12 (86) |
| Cavitary | 7 (58) |
| Drug-resistance profile | |
| MDR | 3 (21) |
| Resistance to INH, RIF, EMB, PZA (AFLDR) | 4 (29) |
| Pre-XDR (FQN-resistant) | 4 (29) |
| XDR | 3 (21) |
| Number of effective drugs in regimen | |
| Intensive phaseb | 7 (5–9) |
| Continuation phasec | 5 (4–6) |
| Duration of MDR therapy, days | 768 (687–858.5) |
| Time on therapy before BDQ start, days | 94 (37–443) |
| Indication for BDQ | |
| Extensive resistance | 8 (57) |
| Rx failure | 1 (7) |
| Intolerance to drugs | 6 (43) |
| Poor clinical response to treatment | 2 (14) |
| Duration of BDQ use, days | 173 (165–193) |
| Payment for BDQ | |
| Private insurance | 5 (36) |
| Government plan | 2 (14) |
| State/local HD | 5 (36) |
| Other | 2 (14) |
| Time to culture conversion, days | 71 (26–116) |
| Treatment outcomes | |
| Completed | 12 (86) |
| Moved out of country | 1 (7) |
| Died on treatment | 1 (7) |
| Patient Characteristics . | No. (%) or Median (IQR) . |
|---|---|
| Age, years | 43.5 (36.5–48.5) |
| Male sex | 10 (71) |
| Previous TB treatment, yes | 5 (36) |
| Positive HIV status | 1 (7) |
| Diabetes, yes | 5 (36) |
| Site of disease | |
| Pulmonary | 14 (100) |
| Both pulmonary and extrapulmonary | 5 (36) |
| Sputum smear positivea | 9 (69) |
| Sputum culture positive | 14 (100) |
| CXR, abnormal | 12 (86) |
| Cavitary | 7 (58) |
| Drug-resistance profile | |
| MDR | 3 (21) |
| Resistance to INH, RIF, EMB, PZA (AFLDR) | 4 (29) |
| Pre-XDR (FQN-resistant) | 4 (29) |
| XDR | 3 (21) |
| Number of effective drugs in regimen | |
| Intensive phaseb | 7 (5–9) |
| Continuation phasec | 5 (4–6) |
| Duration of MDR therapy, days | 768 (687–858.5) |
| Time on therapy before BDQ start, days | 94 (37–443) |
| Indication for BDQ | |
| Extensive resistance | 8 (57) |
| Rx failure | 1 (7) |
| Intolerance to drugs | 6 (43) |
| Poor clinical response to treatment | 2 (14) |
| Duration of BDQ use, days | 173 (165–193) |
| Payment for BDQ | |
| Private insurance | 5 (36) |
| Government plan | 2 (14) |
| State/local HD | 5 (36) |
| Other | 2 (14) |
| Time to culture conversion, days | 71 (26–116) |
| Treatment outcomes | |
| Completed | 12 (86) |
| Moved out of country | 1 (7) |
| Died on treatment | 1 (7) |
N = 14.
Abbreviations: AFLDR, all first-line drug resistant; BDQ, bedaquiline; CXR, chest X-ray; EMB, ethambutol; FQN, fluoroquinolone; HD, health department; HIV, human immunodeficiency virus; INH, isoniazid; IQR, interquartile range; MDR, multidrug-resistant; PZA, pyrazinamide; RIF, rifampin; XDR, extensively drug-resistant; TB, tuberculosis.
aOne smear not done. Denominator out of 13.
bIntensive-phase effective drugs: number of drugs in treatment regimen the patient was sensitive to or otherwise determined effective, while taking any injectable.
cContinuation-phase effective drugs: number of drugs in treatment regimen the patient was sensitive to or otherwise determined effective, after injectables had been discontinued.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
